Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Pancreatic ductal adenocarcinoma is a malignancy with a poor prognosis, with the majority of patients diagnosed with advanced disease on presentation. Treatment options remain limited with little progress over the last 40 years. This review will focus on the current management of metastatic pancreatic ductal adenocarcinoma, with a discussion of new and future treatment strategies based on an improved understanding of tumour biology and mechanisms of pathogenesis.
The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Francesco
F
Sclafani
The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Ridhima
R
Iyer
The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
David
D
Cunningham
The Royal Marsden NHS Foundation Trust, London and Surrey, UK. Electronic address: naureen.starling@rmh.nhs.uk.
Naureen
N
Starling
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007167:Immunotherapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
FOLFIRINOX; Gemcitabine; Nab-paclitaxel; Nanoliposomal irinotecan; Pancreatic adenocarcinoma; Pancreatic cancer; Stroma